Latest Articles

Publication Date
A review on shared genetic architecture of endometriosis and migraine: from pleiotropy to convergent inflammatory pathways.

The comorbidity between endometriosis and migraine has long been recognized clinically, yet a unifying pathophysiological explanation has remained elusive. Traditional models, centered on hormonal fluctuations or secondary inflammation are lacking …

Published: May 15, 2026, midnight
Factors influencing abnormal cleavage of early embryos: time-lapse imaging analysis of 138,178 normally fertilized embryos.

Abnormal cleavage (ABNCL) in early human embryos is a frequent phenomenon associated with impaired developmental competence and reduced reproductive potential. However, the clinical determinants of ABNCL and its subtypes remain …

Published: May 15, 2026, midnight
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer - Minichart

Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer Minichart

Published: May 14, 2026, 4:30 p.m.
Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis - Newswise

Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis Newswise

Published: May 14, 2026, 12:40 p.m.
Karyopharm Therapeut Reports Q1 2026: $35.1M Revenue, $29.2M U.S. Product Sales, Net Loss $22.4M - TradingView

Karyopharm Therapeut Reports Q1 2026: $35.1M Revenue, $29.2M U.S. Product Sales, Net Loss $22.4M TradingView

Published: May 14, 2026, 11:33 a.m.
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - PR Newswire

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment PR Newswire

Published: May 14, 2026, 11:30 a.m.
Press Release: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - Moomoo

Press Release: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment Moomoo

Published: May 14, 2026, 11:30 a.m.
Preliminary Evaluation of Leuprorelin Acetate Microspheres Plus Levonorgestrel-Releasing Intrauterine System in Endometriosis: An Exploratory Study Focusing on BNIP3 and EPAC1 Expression.

This exploratory pilot study aimed to assess the preliminary clinical effects of leuprorelin acetate microspheres for injection [gonadotropin-releasing hormone agonist (GnRH-a)] combined with levonorgestrel-releasing intrauterine system (LNG-IUS) in treating endometriosis …

Published: May 14, 2026, midnight
Exploring the mechanism of plastic additives on reproductive disorders based on network toxicology and molecular docking.

Phthalate esters (PAEs) and organophosphate esters (OPEs) are pervasive 20 environmental pollutants with endocrine-disrupting properties. Despite growing 21 evidence linking PAE/OPE exposure to female reproductive disorders, the 22 diseasespecific molecular …

Published: May 14, 2026, midnight
Diagnosis of Endometriosis: Dual-Amplification Strategy Driven by Copper Nanoclusters.

Endometriosis is a prevalent gynecologic disorder associated with infertility and increased cancer risk, necessitating the development of sensitive and reliable diagnostic methods. Circulating microRNAs (miRNAs) have emerged as promising noninvasive …

Published: May 14, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!